Literature DB >> 17354539

[Intravitreal anti-VEGF injections improve the visual prognosis of wet age related macular degeneration].

Aude Ambresin1, Irmela Mantel.   

Abstract

Age related macular degeneration (AMD) is an ocular disease with high prevalence among elderly persons. Two different forms exist: dry AMD, usually slowly progressive, and neovascular AMD (wet form) more aggressive. Photodynamic therapy is used to treat the wet form and anti VEGF treatments recently became available and offer a real change in the prognostic of wet AMD. Two products are registered and used in Switzerland (Macugen and Lucentis), a third "off labels product", Avastin is also currently used in clinical practice. Nevertheless, both the duration of treatment and the number of injection requested to stabilise the disease were not defined in the studies. Ongoing studies are mainly evaluating combined treatments and long acting form of the drug.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17354539

Source DB:  PubMed          Journal:  Rev Med Suisse        ISSN: 1660-9379


  2 in total

1.  The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues.

Authors:  D Gomika Udugamasooriya; Geoff Dunham; Caroline Ritchie; Rolf A Brekken; Thomas Kodadek
Journal:  Bioorg Med Chem Lett       Date:  2008-07-10       Impact factor: 2.823

2.  Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors.

Authors:  E Moret; A Ambresin; C Gianniou; J Bijon; C Besse-Hayat; S Bogiatzi; D Hohl; F Spertini; I Mantel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-16       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.